Home > Oncology > SABCS 2019 > Phase 3 Trial Update > Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer

Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
SABCS 2019
Metastatic breast cancer patients treated with an oral formulation of paclitaxel and encequidar showed better response, progression-free survival (PFS), and overall survival (OS), as well as less neuropathy compared with patients treated with intravenous paclitaxel. This method of administration may offer patients who do not live near clinics or hospitals a new perspective when this type of treatment is considered. Paclitaxel is generally administered intravenously in the metastatic setting. In this trial, an oral form of the drug was evaluated [1], given in combination with encequidar, which is a highly specific p-glycoprotein pump inhibitor that allows oral paclitaxel to be absorbed into the bloodstream. Researchers enrolled 402 metastatic breast cancer patients who were randomly assigned in a 2:1 ratio to receive either 205 mg/m² of oral paclitaxel plus encequidar for 3 days a week (n=235), or 175 mg/m² paclitaxel intravenously every 3 weeks (n=125). In...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on